Capricor Therapeutics, Inc. (CAPR)
9.40
+0.12
(+1.29%)
USD |
NASDAQ |
Sep 04, 16:00
9.40
0.00 (0.00%)
Pre-Market: 20:00
Capricor Therapeutics Research and Development Expense (Quarterly) : 28.57M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.57M |
| March 31, 2026 | 27.10M |
| December 31, 2025 | 22.88M |
| September 30, 2025 | 20.11M |
| June 30, 2025 | 21.81M |
| March 31, 2025 | 18.70M |
| December 31, 2024 | 14.36M |
| September 30, 2024 | 11.61M |
| June 30, 2024 | 12.30M |
| March 31, 2024 | 10.92M |
| December 31, 2023 | 9.772M |
| September 30, 2023 | 9.866M |
| June 30, 2023 | 8.817M |
| March 31, 2023 | 7.662M |
| December 31, 2022 | 6.232M |
| September 30, 2022 | 5.504M |
| June 30, 2022 | 4.965M |
| March 31, 2022 | 5.116M |
| December 31, 2021 | 4.264M |
| September 30, 2021 | 2.514M |
| June 30, 2021 | 3.497M |
| March 31, 2021 | 3.296M |
| December 31, 2020 | 2.745M |
| September 30, 2020 | 2.629M |
| June 30, 2020 | 1.928M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.155M |
| December 31, 2019 | 0.8287M |
| September 30, 2019 | 0.8578M |
| June 30, 2019 | 1.644M |
| March 31, 2019 | 1.811M |
| December 31, 2018 | 2.849M |
| September 30, 2018 | 3.132M |
| June 30, 2018 | 3.389M |
| March 31, 2018 | 2.696M |
| December 31, 2017 | 2.518M |
| September 30, 2017 | 1.862M |
| June 30, 2017 | 3.128M |
| March 31, 2017 | 3.257M |
| December 31, 2016 | 2.666M |
| September 30, 2016 | 4.727M |
| June 30, 2016 | 4.308M |
| March 31, 2016 | 4.341M |
| December 31, 2015 | 3.331M |
| September 30, 2015 | 3.193M |
| June 30, 2015 | 3.427M |
| March 31, 2015 | 3.807M |
| December 31, 2014 | 2.584M |
| September 30, 2014 | 1.967M |
| June 30, 2014 | 1.856M |
| March 31, 2014 | 1.375M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| REGENXBIO, Inc. | 52.33M |
| Cytokinetics, Inc. | 94.18M |
| Emergent BioSolutions, Inc. | 9.20M |
| Rigel Pharmaceuticals, Inc. | 13.96M |
| United Therapeutics Corp. | 146.30M |